内科学
危险系数
医学
移植
髓系白血病
环磷酰胺
白血病
耐火材料(行星科学)
肿瘤科
累积发病率
胃肠病学
化疗
置信区间
生物
天体生物学
作者
Arnon Nagler,Myriam Labopin,Johanna Tischer,Anna Maria Raiola,Desireé Kunadt,Jan Vydra,Didier Blaise,Patrizia Chiusolo,Renato Fanin,Julia Winkler,Édouard Forcade,Gwendolyn Van Gorkom,Fabio Ciceri,Mohamad Mohty
出处
期刊:Blood Advances
[American Society of Hematology]
日期:2024-04-10
标识
DOI:10.1182/bloodadvances.2024012798
摘要
We compared the outcomes of haploidentical stem cell transplantation (HaploHSCT) with post-transplant cyclophosphamide (PTCy) in 719 patients (pts) with primary refractory (PR) / first relapse (Rel) secondary acute myeloid leukemia (sAML) (n=129) versus those of de novo AML (n=590), transplanted between 2010 and 2022. A higher percentage of pts with sAML versus de novo AML had PR disease (73.6% vs. 58.6%) (p=0.002). In 81.4% of sAML pts, the antecedent hematological disorder was myelodysplastic syndrome. Engraftment was 83.5% vs. 88.4% in sAML and de novo AML, respectively (p=0.13). In multivariate analysis HaploHSCT outcomes did not differ significantly between the groups; non-relapse mortality (NRM) hazard ratio (HR) =1.38 (95% CI 0.96-1.98, p=0.083), relapse incidence (RI) HR= 0.68 (95% CI 0.4.7.-1.00, p=0.051). The HRs for leukemia-free survival (LFS), overall survival (OS), and GVHD-free, relapse-free survival (GRFS) were 0.99 (95% CI 0.76-1.28, p=0.94), 0.99 (95% CI 0.77-1.29, p=0.97) and 0.99 (95% CI 0.77-1.27, p=0.94), respectively. We conclude that outcomes of HaploHSCT with PTCy are not different for PR/Rel sAML in comparison to PR/Rel de novo AML, a finding of major clinical importance.
科研通智能强力驱动
Strongly Powered by AbleSci AI